Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies

Related Keywords

United States ,Philadelphia ,Pennsylvania ,America ,American ,Isabella Zinck ,Thomas Hungerbuehler ,Susanne Schaffert ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Promacta Revolade ,Alina Levchuk ,Twitter ,Drug Administration ,Incyte Corporation As Jakafi ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,American Society Of Hematology ,Novartis Hematology Communications ,Incyte Corporation ,American Society ,Annual Meeting ,First In Human Study ,Charge Platform ,Diffuse Largeb Cell Lymphoma ,Fully Human ,Refractory Multiple Myeloma Manufactured ,Malignant Hematology ,Combination With Hypomethylating Agents ,With Very ,High Risk Myelodysplastic Syndrome ,Acute Myeloid Leukemia ,Final Analysis From ,Safety Results ,Patients With Chronic Myeloid Leukemia ,Chronic Phase After ,Tyrosine Kinase Inhibitors ,Update After ,Open Label ,Randomized Phase ,Once Daily ,Chronic Phase Treated With ,Tyrosine Kinase ,Reported Outcomes ,Among Patients With Steroid Refractory ,Dependent Chronic Graft Vs Host Disease ,Best Available Therapy ,Month Analysis ,Paroxysmal Nocturnal ,Efficacy Results From ,Kids Trial ,Adolescents With Sickle Cell Disease ,Two Antip Selectin Monoclonal Antibodies ,Crizanlizumab Shows Comparable ,Eltrombopag Combined With Cyclosporine ,First Line Therapy ,Adults With Severe Acquired Aplastic Anemia ,Interventional Phase ,Sickle Cell Disease ,National Alliance ,Sickle Cell Centers ,Dharma ,Data ,Spotlight ,Ecently ,Approved ,Scemblix ,Text ,Generation ,Platform ,Xpanding ,Hematology ,Portfolio ,